Treatment of recurrent endometrial adenocarcinoma with a combination of doxorubicin and cisplatin

American Journal of Obstetrics and Gynecology
C TropéG Horváth

Abstract

Nineteen patients with recurrent endometrial carcinoma and one patient with Stage IV endometrial carcinoma not previously treated with chemotherapy were treated with a combination of doxorubicin and cisplatin. The dose schedule was doxorubicin, 50 mg/m2 on day 1, and cisplatin, 50 mg/m2 with hyperhydration on day 1, with a new course every 4 weeks. Objective response 60% was obtained in 12 out of 20 patients (two with complete remission and 10 with partial remission). Furthermore, four patients had stationary disease. The two patients with complete remission both had distal vaginal metastases, and they are still alive after greater than 21 and greater than 40 months. The median survival period for those with partial remission was greater than 11 months (range of 4 to 26); for those with stationary disease, 7 months (range of 4 to 10), and for those with progressive disease, 4 months (range of 3 to 7). The response rate was higher for well-differentiated tumors. No serious side effects were noticed. To our knowledge no other reports have been published so far with the use of the same regimen in patients with recurrent endometrial adenocarcinoma with no prior chemotherapy. We find the objective response rate, the survival time, a...Continue Reading

References

Aug 1, 1980·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·C TropéE Cavallin-Ståhl

❮ Previous
Next ❯

Citations

Jun 8, 2010·International Journal of Clinical Oncology·Atsushi HongoYuji Hiramatsu
Dec 31, 2002·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·F H van WijkUNKNOWN European Organization for Research and Treatment of Cancer. Gynaecological Cancer Group
Jun 1, 1996·American Journal of Clinical Oncology·H L WooP J Hoskins
Sep 1, 2007·Current Opinion in Oncology·Frederic AmantIgnace Vergote
Sep 25, 2009·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Ingeborg B EngelsenHelga B Salvesen
May 4, 2015·Cancer Chemotherapy and Pharmacology·Jesse Lopes da SilvaAndréia Cristina de Melo
Jul 31, 2001·Best Practice & Research. Clinical Obstetrics & Gynaecology·C TropéV M Abeler
Jul 31, 2001·Best Practice & Research. Clinical Obstetrics & Gynaecology·C Steer, P Harper
Nov 28, 2000·Expert Opinion on Investigational Drugs·L Elit, H Hirte
Mar 18, 1999·Hematology/oncology Clinics of North America·M A Quinn
Jan 2, 2007·Cancer Treatment Reviews·D PectasidesT Economopoulos
Oct 15, 1987·Cancer·T ThigpenR McGehee
Oct 13, 2009·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Ingrid VandenputFrédéric Amant
Jan 1, 1990·Medical and Pediatric Oncology·C B VaughnP L Nirenberg
Mar 22, 2014·Molecular and Clinical Oncology·Yuya NogamiDaisuke Aoki
Nov 28, 2012·Asia-Pacific Journal of Clinical Oncology·Giuseppe Colloca, Antonella Venturino
Oct 5, 2015·International Journal of Gynaecology and Obstetrics : the Official Organ of the International Federation of Gynaecology and Obstetrics·Muhieddine SeoudKeiichi Fujiwara
Oct 16, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P J HoskinsN Lee

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.